Joubert Syndrome

Overview

Joubert syndrome (JS) is a rare inherited disorder in which the cerebellum and brainstem do not develop typically before birth. Its defining brain-MRI feature is the “molar tooth sign.” JS is a ciliopathy: the disease-causing genes disrupt primary cilia, tiny cell structures that coordinate developmental signals in many organs. Symptoms vary widely and can include low muscle tone, delayed motor and language development, unsteady movement, abnormal eye movements, breathing irregularities in infancy, and—depending on the gene involved—progressive problems affecting the retina, kidneys, or liver. GeneReviews: Joubert Syndrome

Outlook varies substantially. Some people achieve considerable independence, while others need lifelong support or develop serious kidney, liver, or vision complications. There is currently no approved treatment that corrects the underlying genetic cause or reverses the brain malformation. Standard care is proactive, multidisciplinary management: developmental, physical, occupational, speech, and vision therapies; monitoring for sleep and breathing problems; and gene-informed surveillance of kidney, liver, and retinal health. GeneReviews: Joubert Syndrome

Scope of Recent Research (2020–present)

Research activity since 2020 has been meaningful but remains predominantly at the discovery and preclinical stage rather than the therapeutic-development stage. The field’s central questions are which genetic changes cause JS, why mutations in different ciliary genes lead to different organ risks, and which cellular pathways can be safely modified. Better diagnosis, patient-derived disease models, and identification of potentially druggable pathways are advancing, but the community is not yet close to a broadly applicable curative therapy. Phenotypic variability and ciliary pathophysiology Joubert syndrome molecular basis and treatment

Major Breakthroughs and Emerging Therapies

Precision diagnosis and gene-targeted readiness. A major recent advance is improved identification of the exact genetic cause. In a 2025 multicenter study, reanalysis of existing exome-sequencing data for copy-number and hidden intronic splice variants supplied a definitive diagnosis for 17 of 70 previously unresolved cases, a 24% overall diagnostic gain. This is not a treatment by itself, but it is essential groundwork for future mutation-specific therapies such as RNA splicing correction, gene replacement, or gene editing. Cryptic variants improve diagnostic yield

Patient-derived stem-cell models. Researchers are now using induced pluripotent stem cells (iPSCs)—adult patient cells reset into stem-like cells—to study JS in developing human neurons. A 2024 study found that iPSCs from people with JS showed impaired formation of mid-hindbrain and cerebellar-granule-cell lineages and abnormal primary-cilium number and shape during differentiation. A separate 2023 project created a validated iPSC line from a person with CPLANE1-related JS. These platforms can test candidate drugs or gene-correction strategies in cells carrying a patient’s own variants, but they have not yet produced a clinical treatment. JS iPSCs show altered neuronal differentiation CPLANE1 JS iPSC line

Small-molecule pathway targeting for kidney disease. A 2025 study in a Xenopus frog model of CEP290-related Joubert-spectrum disease found abnormal activation of the IL-6/JAK/STAT3/FOSL1 inflammatory-signaling pathway in developing kidneys. The JAK inhibitor ruxolitinib reduced kidney-tubule dilation in the model. This identifies a possible drug-repurposing lead for cystic or nephronophthisis-like kidney disease, but it is early preclinical evidence in embryos—not evidence that ruxolitinib is safe or effective for people with JS. JAK/STAT3 inhibition in a Joubert-related kidney model

Gene and RNA therapy remain prospective rather than clinical for JS. The genetic heterogeneity of JS is a central barrier: more than 40 genes have been linked to the condition, and different genes can produce different combinations of brain, retinal, renal, and hepatic disease. Research on genotype–phenotype relationships is increasingly allowing risk-stratified care and may ultimately identify the subgroups most suitable for gene-specific medicines. However, no gene-replacement, gene-editing, antisense-RNA, cell, or small-molecule therapy has yet been established as disease-modifying for Joubert syndrome itself. Genotype–phenotype correlates in JS Phenotypic variability and ciliary pathophysiology

Clinical Trials and Experimental Approaches

As of October 19, 2026, registered JS research is centered on observational cohorts, biospecimen collection, natural history, and genetic discovery rather than interventional cure trials. The active ARPKD Database Study, sponsored by Children’s Hospital of Philadelphia with National Institute of Diabetes and Digestive and Kidney Diseases collaboration, includes JS within a broader hepato-renal fibrocystic-disease registry. It is recruiting, plans enrollment of 200 participants, and is estimated to complete in December 2030; it does not test a drug or gene therapy. ARPKD Database Study, NCT01401998

The principal completed JS-specific registry study, JSCORS, was sponsored by Assistance Publique–Hôpitaux de Paris and examined the prevalence and clinical correlations of AHI1, CEP290, and NPHP1 changes using blood samples. It was observational, not therapeutic, and no results were posted on the registry. Its legacy is the genetic and clinical characterization needed to design future targeted trials. JSCORS, NCT00873678

Methodologies and Scientific Approaches

Current JS research combines genome and RNA sequencing with functional follow-up. Investigators use exome-data reanalysis to detect copy-number changes and deep intronic variants that alter RNA splicing; they then validate findings with methods such as RT-PCR, minigene assays, chromosomal microarrays, and quantitative PCR. These approaches improve molecular diagnoses and can identify patients whose variants might be amenable to RNA-directed medicines in the future. Cryptic variants improve diagnostic yield

Disease mechanisms are being studied in patient fibroblasts, iPSC-derived neural cells, standard ciliated cell lines, and animal models such as Xenopus. Important readouts include cilium formation and structure, trafficking of proteins into cilia, neuronal differentiation, kidney-tubule shape, gene-expression patterns, MRI-defined brain anatomy, kidney function, retinal status, and liver disease. JS iPSCs show altered neuronal differentiation ARL13B cilia-function study JAK/STAT3 inhibition in a Joubert-related kidney model

Leading Institutions and Funding

Important JS research centers include the University of Washington’s Hindbrain Malformation Research Program, the University of Pavia and IRCCS Mondino Foundation in Italy, and the North East Genomics Clinic at Newcastle upon Tyne NHS Foundation Trust in the United Kingdom. These groups contribute to variant interpretation, genotype–phenotype studies, patient cohorts, and experimental disease models. GeneReviews: Joubert Syndrome

Representative support includes NIH awards to JS research in the Doherty laboratory, including R01HD100730 and R01NS064077, and Italian funding to the Valente laboratory through Fondazione Telethon grant GGP20070, the Italian Ministry of Health’s Ricerca Finalizzata program, and the Fondazione Mariani Padaport project. The Joubert Syndrome & Related Disorders Foundation is a volunteer-run patient organization that provides family-oriented grants for assistive technology, therapy costs, home modifications, education, and crisis support; its listed grants are not disease-directed research awards. Recurrent and hypomorphic JS variants Telethon-supported iPSC research JSRDF grants

Strengths, Limitations, and Challenges

The strongest recent progress is the convergence of molecular diagnosis and biologically relevant models. Researchers can increasingly identify hidden disease-causing variants, predict organ-specific risks from the causative gene, and test mechanisms in patient-derived neural cells rather than relying only on nonhuman systems. The discovery that progressive end-organ disease differs by genetic subgroup makes personalized monitoring immediately useful and could eventually enable genetically stratified treatment trials. Phenotypic variability and ciliary pathophysiology Genotype–phenotype correlates in JS

The limitations are substantial. JS begins during fetal brain development, so a therapy given after birth may be able to protect remaining retinal, kidney, or liver function but may not reverse established cerebellar and brainstem malformations. The large number of causal genes makes a single gene therapy unlikely to serve everyone, while delivery of genetic medicines to the brain, kidney, retina, and liver presents different technical and safety problems. Small-molecule findings such as ruxolitinib in frog embryos require replication in mammalian models, dose studies, and carefully designed human trials before clinical use can be justified. JAK/STAT3 inhibition in a Joubert-related kidney model Joubert syndrome molecular basis and treatment

Outlook and Future Directions

A cure for Joubert syndrome is not imminent as of October 19, 2026. The most realistic nearer-term advances are earlier and more complete genetic diagnosis, gene-specific surveillance, improved developmental and vision rehabilitation, and treatments that preserve kidney, retinal, or liver function in defined subgroups. Milestones worth watching are replication of pathway-targeting results in mammalian models, development of validated outcome measures and natural-history cohorts, and the first registered interventional trial designed specifically for a genetically defined JS subgroup. ARPKD Database Study, NCT01401998 Cryptic variants improve diagnostic yield

References

• GeneReviews: Joubert Syndrome — NCBI Bookshelf, 2026.
• Joubert syndrome molecular basis and treatment — Spahiu et al., 2022.
• Phenotypic variability and ciliary pathophysiology — Owens et al., 2024.
• Cryptic variants improve diagnostic yield — D’Abrusco et al., 2025.
• JS iPSCs show altered neuronal differentiation — De Mori et al., 2024.
• CPLANE1 JS iPSC line — Tardivo et al., 2023.
• JAK/STAT3 inhibition in a Joubert-related kidney model — Uuganbayar et al., 2025.
• Genotype–phenotype correlates in JS — Gana, Serpieri, and Valente, 2022.
• ARPKD Database Study, NCT01401998 — ClinicalTrials.gov, 2026.
• JSCORS, NCT00873678 — ClinicalTrials.gov, 2010.
• ARL13B cilia-function study — Lin et al., 2024.
• Recurrent and hypomorphic JS variants — Gana et al., 2023.
• Telethon-supported iPSC research — De Mori et al., 2024.
• JSRDF grants — Joubert Syndrome & Related Disorders Foundation, 2026.